With the emergence of new data on IL28B, it is expected to be involved in upcoming trials to update these algorithms.In conclusion, besides viral factors, several host factors are responsible for the responsiveness to HCV therapy with Peg-IFN-α/RBV, including host genetic factors, age, ethnicity, gender, menopause, cirrhosis, BMI, steatosis, IR, and T2DM. The gene discussed is IFNA1; the disease is type 2 diabetes mellitus.